Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
 - EconoTimes)
NEW ORLEANS, March 03, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 13, 2017 to file lead plaintiff applications in a securities class action lawsuit against Novo Nordisk A/S (NYSE:NVO), if they purchased the Company’s American Depository Receipts (“ADRs”) between the expanded period of February 5, 2015 and October 27, 2016, inclusive (the “Class Period”). The action is pending in the United States District Court for the District of New Jersey.
What You May Do
If you purchased ADRs of Novo Nordisk and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 13, 2017.
About the Lawsuit
Novo Nordisk and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 5, 2016, the Company announced disappointing earnings for the 2016 second quarter. Then, on October 28, 2016, the Company disclosed that it was cutting its long-term profit growth by 50% and that it had received a Civil Investigative Demand from the U.S. Attorney’s Office for the Southern District of New York seeking information relating to contracts and business relationships concerning its insulin products.
On this news, the price of Novo Nordisk’s ADRs plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
